LIXTW Stock Financial Analysis - Lixte Biotechnology Holdings, Inc.

Quality, Value, Momentum Scores

This card shows the Quality, Value, and Momentum scores for the company

Quality

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Value

Proprietary scoring model that ranks companies based on their relative valuation. Scores range from 0 to 100, with 100 being the most undervalued.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Fund Sentiment

The Fund Sentiment (fka Ownership) score is a proprietary quantitative model that ranks companies based on levels of ownership accumulation.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Income Statement: Revenue, Operating Income, Net Income

The operating income for Lixte Biotechnology Holdings, Inc. - Equity Warrant as of June 30, 2025 is -3.08 MM.
The net income for Lixte Biotechnology Holdings, Inc. - Equity Warrant as of June 30, 2025 is -3.09 MM.

Period End (TTM)	Revenue (MM)	Operating Income (MM)	Net Income (MM)
2025-06-30		-3.08	-3.09
2025-03-31		-3.31	-3.32
2024-12-31		-3.57	-3.59
2024-09-30		-3.99	-4.00
2024-06-30		-4.03	-4.03
2024-03-31		-4.69	-4.69
2023-12-31		-5.09	-5.09
2023-09-30		-5.70	-5.69
2023-06-30		-6.15	-6.15
2023-03-31		-6.03	-6.02
2022-12-31		-6.31	-6.31
2022-09-30		-6.70	-6.71
2022-06-30		-6.46	-6.47
2022-03-31		-6.65	-6.66
2021-12-31		-6.72	-6.73
2021-09-30		-5.60	-5.61
2021-06-30		-5.96	-5.97
2021-03-31		-4.60	-4.61
2020-12-31		-3.27	-3.26
2020-09-30		-2.69	-2.68

Income Statement: EPS

The earnings per share basic for Lixte Biotechnology Holdings, Inc. - Equity Warrant as of June 30, 2025 is -1.27.
The earnings per share diluted for Lixte Biotechnology Holdings, Inc. - Equity Warrant as of June 30, 2025 is -1.27.

Period End (TTM)	Earnings Per Share Basic	Earnings Per Share Diluted
2025-06-30	-1.27	-1.27
2025-03-31	-1.44	-1.44
2024-12-31	-1.59
2024-09-30	-1.78	-1.78
2024-06-30	-1.83	-1.83
2024-03-31	-2.27	-2.28
2023-12-31	-2.66
2023-09-30	-3.21	-3.21
2023-06-30	-3.69	-3.69
2023-03-31	-3.64	-3.64
2022-12-31	-3.99	-3.99
2022-09-30	-4.45	-4.45
2022-06-30	-4.51	-4.51
2022-03-31	-4.85	-4.85
2021-12-31	-4.99
2021-09-30	-4.33	-4.33
2021-06-30	-4.86	-4.86
2021-03-31	-3.95	-3.95
2020-12-31	-2.90
2020-09-30	-2.40	-2.40

Cash Flow: Operations, Investing, Financing

The cash from operating activities for Lixte Biotechnology Holdings, Inc. - Equity Warrant as of June 30, 2025 is -2.61 MM.
The cash from financing activities for Lixte Biotechnology Holdings, Inc. - Equity Warrant as of June 30, 2025 is 0.90 MM.

Period End (TTM)	Cash From Operating Activities (MM)	Cash From Investing Activities (MM)	Cash From Financing Activities (MM)
2025-06-30	-2.61		0.90
2025-03-31	-2.94		0.91
2024-12-31	-3.16
2024-09-30	-3.47		0.00
2024-06-30	-3.45		3.14
2024-03-31	-3.81		3.14
2023-12-31	-4.29		3.14
2023-09-30	-4.60		3.14
2023-06-30	-4.83		0.01
2023-03-31	-4.85		5.16
2022-12-31	-4.61		5.14
2022-09-30	-4.55		5.15
2022-06-30	-4.30		5.24
2022-03-31	-4.15		0.19
2021-12-31	-4.14		3.90
2021-09-30	-3.74		8.62
2021-06-30	-3.43		8.46
2021-03-31	-2.74		8.30
2020-12-31	-2.13		4.60
2020-09-30	-1.77		-0.13

Valuation Metrics : PE, PriceToBook, PriceToTBV

P/Book: The current closing price divided by the book value per share.

P/TBV: The current price divided by the tangible book value per share.

Period End (TTM)	p/e	P/Book	P/TBV
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30

Valuation Metrics : EBitToEv, EBit3YrAvgToEv

Period End (TTM)	EBIT/EV	EBIT (3y)/EV
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30

Management Effectiveness

The roa for Lixte Biotechnology Holdings, Inc. - Equity Warrant as of June 30, 2025 is -1.25.
The roe for Lixte Biotechnology Holdings, Inc. - Equity Warrant as of June 30, 2025 is -1.48.
The roic for Lixte Biotechnology Holdings, Inc. - Equity Warrant as of June 30, 2025 is -2.87.
The croic for Lixte Biotechnology Holdings, Inc. - Equity Warrant as of June 30, 2025 is -1.75.
The ocroic for Lixte Biotechnology Holdings, Inc. - Equity Warrant as of June 30, 2025 is -2.54.

Period End (TTM)	ROA	ROE	ROIC	CROIC	OCROIC
2025-06-30	-1.25	-1.48	-2.87	-1.75	-2.54
2025-03-31	-0.93	-1.06	-2.87	-1.75	-2.54
2024-12-31	-0.83	-0.90	-4.33	-3.83	-3.83
2024-09-30	-0.76	-0.81	-2.93	-2.54	-2.54
2024-06-30	-1.08	-1.15	-1.50	-0.22	-1.22
2024-03-31		-0.98
2023-12-31			-1.16	-0.30
2023-09-30			-2.28	-1.79
2023-06-30		-0.82	-2.28	-1.79
2023-03-31		-1.73	-1.48	0.08
2022-12-31
2022-09-30
2022-06-30		0.00
2022-03-31		0.00	0.00
2021-12-31		0.00
2021-09-30	0.00	0.00
2021-06-30	-3.16		-0.87	0.73	-0.50
2021-03-31	-2.02	-2.25	-0.60	0.73	-0.36
2020-12-31	-1.22	-1.34	-0.65	0.49	-0.43
2020-09-30	-0.87	-0.97	-2.35	-1.67	-1.55

Gross Margins

Gross Margin: The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.

Net Margin: The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.

Operating Margin: The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.

Period End (TTM)	Gross Margin	Net Margin	Operating Margin
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30

LIXTW Stock Financial Analysis - Lixte Biotechnology Holdings, Inc. - Equity Warrant (NasdaqCM) Stock